Pyrazolopyrazine compound and method for preparing crystal form thereof
By employing a chiral resolution method using chiral reagents and specific solvent systems, the problems of insufficient selectivity and high synthesis cost of TYK2 kinase inhibitors have been solved. This method achieves effective inhibition of TYK2 and JAK2 and improves compound purity, resulting in good in vivo efficacy and chemical stability.
Patent Information
- Application Number
- PCT/CN2024/092691
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-21
AI Technical Summary
Existing technologies are unable to effectively inhibit TYK2 kinase, resulting in insufficient selectivity in the treatment of inflammatory and autoimmune diseases. Furthermore, the synthesis of pyrazolopyrazine compounds involves expensive processes using precious metal catalysts and chiral SFC separation.
Chiral resolution of compound q was achieved using chiral reagents (R)-(+)-N-benzyl-1-phenylethylamine and (S)-(-)-N-benzyl-1-phenylethylamine. By combining specific solvent ratios and temperature control, noble metal catalysts were avoided. Selective alkylation and chiral resolution were used to improve the reaction yield and purity.
Selective inhibition of TYK2 and JAK2 was achieved, reducing synthesis costs, improving compound purity and reaction efficiency, and exhibiting good in vivo efficacy and chemical stability.
Smart Images

Figure CN2024092691_21112024_PF_FP_ABST
Abstract
Description
A method for preparing a pyrazolopyrazine compound and its crystal form
[0001] This application claims priority to
[0002] This application claims priority to and the benefits of Chinese Patent Application No. 2023105446906 filed with the State Intellectual Property Office of China on May 12, 2023, and the contents disclosed in said application are incorporated herein by reference in their entirety. Technical Field
[0003] The present invention relates to a method for preparing a pyrazolopyrazine compound and a crystal form thereof, and particularly relates to a method for preparing a compound of formula (I) and a crystal form thereof. Background Art
[0004] Janus kinases (JAKs) are cytoplasmic tyrosine kinases that mediate cytokine signals from membrane receptors to STAT transcription factors. The JAK family consists of four members: JAK1, JAK2, JAK3, and TYK2. The JAK-STAT pathway transmits extracellular signals from a variety of cytokines, growth factors, and hormones to the cell nucleus and is responsible for the expression of thousands of protein-coding genes. The JAK-STAT pathway converts extracellular signals into transcriptional responses through several steps: 1) When cell surface cytokine receptors bind to their respective cytokine ligands, conformational changes occur, leading to receptor dimerization. This brings the receptor-bound JAK kinases into close proximity and leads to activation through reciprocal tyrosine phosphorylation. 2) Activated JAKs catalyze the phosphorylation of tyrosine residues on the receptors. These phosphorylated tyrosine residues then form "docking sites" with the surrounding amino acid sequence, recruiting STAT proteins containing SH2 domains to these docking sites. 3) Finally, the kinase JAK catalyzes the phosphorylation of STAT proteins bound to the receptor. Activated STAT proteins then leave the receptor and form dimers, then translocate to the cell nucleus to regulate the transcription of specific genes. JAK-STAT intracellular signaling serves interferons, most interleukins, and a variety of cytokines and endocrine factors, such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF, and PRL (Vainchenker WE Tal. (2008)).
[0005] Different JAK family members selectively bind to different cytokine receptors, conferring signal transduction specificity and thus exerting different physiological effects. This selective mode of action allows JAK inhibitors to be used relatively specifically for disease treatment. TYK2 is a member of the JAK kinase family and a key mediator of signal transduction for inflammatory cytokines such as IL-12, IL-23, and type I interferons. These cytokines are implicated in the pathogenesis of various inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE). Therefore, developing inhibitors with high inhibitory activity against TYK2 and certain inhibitory activity against JAK2 and JAK1 can maximize the inhibition of the intracellular formation of heterodimers between TYK2, JAK2, and JAK1, thereby blocking the signal transduction pathway and thereby blocking the signal transduction of inflammatory cytokines IL-12, IL-23, and type I interferons, thereby treating specific diseases.
[0006] Summary of the Invention
[0007] The present invention provides a method for preparing a compound of formula (I).
[0008] Characterized in that it includes a chiral resolution method for compound q,
[0009] in,
[0010] The chiral reagent is selected from chiral reagent 1 or chiral reagent 2;
[0011] The chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, and the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine;
[0012] The mixed solvent is selected from solvent 2 and solvent 3;
[0013] The solvent 2 is tetrahydrofuran, and the solvent 3 is water.
[0014] In some embodiments of the present invention, the molar ratio of the compound q to the chiral reagent is 1:2 to 1:2.5, preferably 1:2.1, and other variables are as defined in the present invention.
[0015] In some embodiments of the present invention, the volume ratio of the mixed solvent is tetrahydrofuran:water = 15:1 to 20:1; preferably 16.5:1, and other variables are as defined in the present invention.
[0016] In some embodiments of the present invention, the chiral resolution method of compound q further comprises a step of further purification, and other variables are as defined in the present invention.
[0017] In some embodiments of the present invention, the chiral resolution and purification method of compound q comprises the following steps: adding solvent 2, solvent 3, compound q, and chiral reagent 1 to a reaction vessel in sequence at 20-30°C, stirring at 20-30°C for 1 hour, heating to 73°C and stirring for 2 hours, cooling naturally to 20-30°C, and stirring at this temperature for 12 hours. The reaction solution is filtered, and the filter cake is washed three times with a mixture of solvent 2 and solvent 3. The filtrate is concentrated under reduced pressure, slurried with aqueous sodium carbonate solution for 1 hour, ethyl acetate is added, stirring is continued for 1 hour, and the layers are allowed to stand for separation. The aqueous phase is then washed with ethyl acetate, and the two organic phases are discarded. The aqueous phase is pumped into a reaction vessel, and solvent 15 is added, so that the solvents in the reaction vessel now consist of water and solvent 15. The pH is adjusted to 4-5 with concentrated hydrochloric acid, and stirred at 20-30°C for 12 hours. Solids are generated, and the reaction solution is filtered. The resulting filter cake is vacuum-dried at 70°C for 12 hours to obtain a crude compound r. At 20-30°C, solvent 2, solvent 3, the crude compound r, and chiral reagent 2 were added sequentially to a reaction vessel, stirred at 20-30°C for 1 hour, heated to 73°C and stirred for 2 hours, cooled naturally to 20-30°C, and stirred at this temperature for 12 hours. The reaction solution was filtered, and the filter cake was washed three times with a mixture of solvent 2 and solvent 3. At 20-30°C, solvent 2, solvent 3, and the filter cake were added sequentially to a reaction vessel, stirred at 20-30°C for 1 hour, heated to 73°C and stirred for 2 hours, cooled naturally to 20-30°C, and stirred at this temperature for 12 hours. The reaction solution was filtered, and the filter cake was washed three times with a mixture of solvent 2 and solvent 3. The filter cake was slurried with aqueous sodium carbonate solution for 1 hour, ethyl acetate was added, and stirring was continued for 1 hour. The mixture was allowed to stand for separation, and the aqueous phase was washed again with ethyl acetate. The two organic phases were discarded. The aqueous phase was pumped into a reactor, and acetonitrile was added, leaving the reaction vessel with water and solvent 15. The pH was adjusted to 4-5 with concentrated hydrochloric acid and stirred at 20-30°C for 12 hours. Solids formed, and the reaction solution was filtered. The filter cake was vacuum-dried at 70°C for 12 hours to yield compound r. SFC analysis (column type: Chiralcel OJ-3 100*4.6mm ID, 3μm; mobile phase: A: CO2; B: methanol (0.05% diethylamine); phase B gradient: 5%-40% for 4 minutes, hold at 40% for 2.5 minutes, 5% for 1.5 minutes; flow rate: 2.8 mL / min); retention time: 3.285 minutes; ee% = 99.02%.
[0018] In some embodiments of the present invention, the solvent 2 is tetrahydrofuran, the solvent 3 is water, the solvent 15 is acetonitrile, the chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine, and the other variables are as defined herein.
[0019] In some embodiments of the present invention, the volume ratio of solvent 2 to solvent 3 is 15:1 to 20:1, preferably 16.5:1, and other variables are as defined in the present invention.
[0020] In some embodiments of the present invention, the volume ratio of water to solvent 15 is 5:1 to 15:1, preferably 10:1, and other variables are as defined in the present invention.
[0021] In some embodiments of the present invention, the molar ratio of the compound q to the chiral reagent 1 is 1:2 to 1:2.5, preferably 1:2.1, and other variables are as defined in the present invention.
[0022] In some embodiments of the present invention, the molar ratio of the crude compound r to the chiral reagent 2 is 1:2 to 1:2.5, preferably 1:2.1, and other variables are as defined in the present invention.
[0023] The present invention provides a method for preparing a compound of formula (I), which comprises selectively alkylating compound d and compound e.
[0024] in,
[0025] Reagent 1 is magnesium bromide;
[0026] Base 2 is DIEA;
[0027] Solvent 4 is tetrahydrofuran.
[0028] In some embodiments of the present invention, the selective alkylation method of compound d and compound e comprises the following steps: dissolving compound e and compound d in solvent 4, adding reagent 1 after clear dissolution, slowly adding base 2 dropwise at 15-20°C, maintaining the temperature and continuing the reaction to obtain compound f.
[0029] In some embodiments of the present invention, the reagent 1 is magnesium bromide, the base 2 is DIEA, the solvent 4 is tetrahydrofuran, and other variables are as defined in the present invention.
[0030] In some embodiments of the present invention, the molar ratio of compound e to compound d is 1:0.8 to 1:1.2, preferably 1:1, and other variables are as defined in the present invention.
[0031] In some embodiments of the present invention, the molar ratio of compound e, compound d and reagent 1 is 1:0.8:0.1 to 1:1.2:0.3, preferably 1:1:0.2, and other variables are as defined in the present invention.
[0032] In some embodiments of the present invention, the time for adding the base 2 dropwise is 2 to 4 hours, preferably 3 hours, and other variables are as defined in the present invention.
[0033] In some embodiments of the present invention, the reaction time is 10 to 20 hours, preferably 15 hours, and other variables are as defined in the present invention.
[0034] The present invention provides a method for preparing the compound of formula (I), which comprises the following reaction scheme:
[0035] The present invention provides a method for preparing a compound of formula (I), which comprises synthesizing compound r from compound o,
[0036] The equivalent ratio of compound o to compound k is 1:0.9 to 1:1.2;
[0037] The base 1 is selected from DBU;
[0038] The solvent 1 is selected from acetonitrile;
[0039] The alkaline system 1 is selected from an aqueous sodium hydroxide solution;
[0040] The acidic system 1 is selected from concentrated hydrochloric acid;
[0041] The chiral reagent is selected from chiral reagent 1 or chiral reagent 2;
[0042] The chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, and the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine;
[0043] The mixed solvent is selected from solvent 2 and solvent 3;
[0044] The solvent 2 is tetrahydrofuran, and the solvent 3 is water.
[0045] In some embodiments of the present invention, the reaction temperature for preparing compound p from compound o and compound k is 85-95°C, preferably the internal temperature of the reaction is 82°C, and other variables are as defined in the present invention.
[0046] In some embodiments of the present invention, the equivalent ratio of compound o to compound k is 1:1, and other variables are as defined in the present invention.
[0047] The present invention provides a method for preparing the compound of formula (I), which comprises the following reaction scheme:
[0048] The present invention provides a method for preparing the compound of formula (I), which comprises the following reaction scheme:
[0049] The present invention provides a method for preparing a compound of formula (I), which includes a method for synthesizing intermediate k.
[0050] The reagent 1 is selected from magnesium bromide;
[0051] The base 2 is selected from DIEA;
[0052] The solvent 4 is selected from tetrahydrofuran;
[0053] The reagent 2 is selected from ammonium acetate;
[0054] The solvent 5 is selected from ethanol;
[0055] The halogenating agent is selected from phosphorus oxychloride;
[0056] The solvent 6 is selected from acetonitrile;
[0057] The catalyst is selected from [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride;
[0058] The base 3 is selected from sodium carbonate;
[0059] The solvent 7 is selected from dioxane;
[0060] The solvent 8 is selected from water;
[0061] The acidic system 2 is selected from hydrochloric acid / ethyl acetate solution;
[0062] The solvent 9 is selected from dichloromethane.
[0063] In some embodiments of the present invention, the volume ratio of the solvent 7 to the solvent 8 is 4:1 to 6:1, preferably 5:1, and other variables are as defined in the present invention.
[0064] In some embodiments of the present invention, the molar ratio of compound h, compound i, catalyst and base 3 is 1:0.9:0.01:2 to 1:1.2:0.05:3, preferably 1:1.05:0.03:2.5, and other variables are as defined in the present invention.
[0065] In some embodiments of the present invention, the concentration of the hydrochloric acid / ethyl acetate solution is 3 to 5 M, preferably 4 M, and other variables are as defined in the present invention.
[0066] The present invention provides a method for preparing the compound of formula (I), which further comprises the following reaction steps:
[0067] The present invention provides a method for preparing a compound of formula (I), which also includes a method for synthesizing a compound of formula (I) from compound 1.
[0068] The acidic system 3 is selected from sulfuric acid;
[0069] The solvent 10 is selected from ethanol;
[0070] The base 4 is selected from triethylamine;
[0071] The solvent 11 is selected from tetrahydrofuran;
[0072] The reagent 3 is selected from lithium bromide;
[0073] The solvent 1 is selected from acetonitrile;
[0074] The alkaline system 1 is selected from an aqueous sodium hydroxide solution;
[0075] The acidic system 1 is selected from concentrated hydrochloric acid;
[0076] The chiral reagent is selected from chiral reagent 1 or chiral reagent 2;
[0077] The chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, and the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine;
[0078] The mixed solvent is selected from solvent 2 and solvent 3;
[0079] The solvent 2 is tetrahydrofuran, and the solvent 3 is water;
[0080] The reagent 4 is selected from ammonium chloride;
[0081] The base 5 is selected from DIEA;
[0082] The condensing agent is selected from HATU;
[0083] The solvent 12 is selected from DMF;
[0084] The reagent 4 is selected from trifluoroacetic anhydride;
[0085] The base 6 is selected from triethylamine;
[0086] The solvent 13 is selected from dichloromethane;
[0087] The solvent 14 is selected from methanol.
[0088] The present invention provides a Form 1 crystalline form of the compound of formula (I),
[0089] The invention is characterized in that its Cu Kα radiation X-ray powder diffraction spectrum has characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200° and 12.852±0.200°.
[0090] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum, expressed as 2θ angles, comprising at least 6, 7, 8 or 9 diffraction peaks selected from the following: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, and 20.666±0.200°.
[0091] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum having characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200° and 19.105±0.200°.
[0092] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum, expressed as 2θ angles, comprising at least 11, 12, 13 or 14 diffraction peaks selected from the following: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 19.710±0.200°, 20.890±0.200°, 21.900±0.200°, 22.457±0.200°, 23.340±0.200°, 24.910±0.200°, 25.910±0.200°, 26.910±0.200°, 27.910±0.200°, 28. 0°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°, 20.875±0.200°, 21.210±0.200°, 22.417±0.200°, 23.446±0.200°, 24.043±0.200°.
[0093] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum having characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°, 20.875±0.200° and 21.210±0.200°.
[0094] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum, expressed as 2θ angles, comprising at least 16, 17, 18, 19, 20, 21, 22 or 23 diffraction peaks selected from the following: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°. °, 20.875±0.200°, 21.210±0.200°, 22.417±0.200°, 23.446±0.200°, 24.043±0.200°, 24.402±0.200°, 25.159±0.200°, 26.227±0.200°, 26.742±0.200°, 26.897±0.200°, 27.725±0.200°, 30.956±0.200°, 32.574±0.200°, 34.479±0.200°.
[0095] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum having characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°, 20.875±0.200°, 21.210±0.200°, 22.417±0.200°, 23.446±0.200°, 24.043±0.200° and 24.402±0.200°.
[0096] In some embodiments of the present invention, the Form 1 crystalline form of the compound of formula (I) has an X-ray powder diffraction spectrum having characteristic diffraction peaks at the following 2θ angles: 6.516°, 8.087°, 9.378°, 11.188°, 11.881°, 12.852°, 13.880°, 14.564°, 15.615°, 16.163°, 18.306°, 18.626°, 19.105°, 19.477°, 20.666°, 20.875°, 21.210°, 22.417°, 23.446° , 23.715°, 24.043°, 24.402°, 25.159°, 25.663°, 26.227°, 26.742°, 26.897°, 27.127°, 27.752°, 28.341°, 29.332°, 30.727°, 30.956°, 31.678°, 32.197°, 32.574°, 34.479°, 35.051°, 35.341°, 35.873°, 36.960°.
[0097] In some embodiments of the present invention, the XRPD pattern of the Form 1 crystalline form of the compound of formula (I) is shown in FIG1 .
[0098] In some embodiments of the present invention, the differential scanning calorimetry (DSC) curve of the Form 1 crystalline form of the compound of formula (I) above shows an endothermic peak starting point at 161.77°C ± 3.00°C.
[0099] In some embodiments of the present invention, the DSC spectrum of the Form 1 crystal form of the compound of formula (I) is shown in FIG2 .
[0100] In some embodiments of the present invention, the thermogravimetric analysis (TGA) curve of the Form 1 crystalline form of the compound of formula (I) shows a weight loss of 0.3182% at 150.00°C±3.00°C.
[0101] In some embodiments of the present invention, the TGA spectrum of the Form 1 crystal form of the compound of formula (I) is shown in FIG3 .
[0102] In some embodiments of the present invention, the peak positions and relative intensities of the diffraction peaks in the Cu Kα radiation XRPD pattern of the Form 1 crystal form of the compound of formula (I) are shown in Table 1 below:
[0103] Table 1. XRPD pattern analysis data of Form 1 crystal form of the compound of formula (I)
[0104] The present invention provides a nearly amorphous form of the compound of formula (I),
[0105] The invention is characterized in that its Cu Kα radiation X-ray powder diffraction spectrum has characteristic diffraction peaks at the following 2θ angles: 4.341±0.200°, 5.082±0.200° and 6.921±0.200°.
[0106] In some embodiments of the present invention, the nearly amorphous form of the compound of formula (I) has an X-ray powder diffraction spectrum, expressed as 2θ angles, comprising at least 4, 5 or 6 diffraction peaks selected from the following: 4.341±0.200°, 5.082±0.200°, 6.921±0.200°, 18.955±0.200°, 23.319±0.200°, and 26.108±0.200°.
[0107] In some embodiments of the present invention, the nearly amorphous form of the compound of formula (I) has an X-ray powder diffraction spectrum with characteristic diffraction peaks at the following 2θ angles: 4.341±0.200°, 5.082±0.200°, 6.921±0.200° and 18.955±0.200°.
[0108] In some embodiments of the present invention, the near-amorphous form of the compound of formula (I) has an X-ray powder diffraction spectrum with characteristic diffraction peaks at the following 2θ angles: 4.341±0.200°, 5.082±0.200°, 6.921±0.200°, 18.955±0.200° and 23.319±0.200°.
[0109] In some embodiments of the present invention, the amorphous form of the compound of formula (I) has an X-ray powder diffraction spectrum with characteristic diffraction peaks at the following 2θ angles: 4.341°, 5.082°, 6.921°, 18.955°, 23.319°, and 26.108°.
[0110] In some embodiments of the present invention, the XRPD pattern of the nearly amorphous compound of formula (I) is shown in FIG4 .
[0111] In some embodiments of the present invention, the differential scanning calorimetry (DSC) curve of the nearly amorphous compound of formula (I) above shows an endothermic peak starting point at 76.70°C ± 3.00°C.
[0112] In some embodiments of the present invention, the DSC spectrum of the nearly amorphous compound of formula (I) is shown in FIG5 .
[0113] In some embodiments of the present invention, the thermogravimetric analysis (TGA) curve of the nearly amorphous compound of formula (I) shows a weight loss of 1.869% at 150.00°C±3.00°C.
[0114] In some embodiments of the present invention, the TGA spectrum of the nearly amorphous compound of formula (I) is shown in FIG6 .
[0115] In some embodiments of the present invention, the peak positions and relative intensities of the diffraction peaks in the Cu Kα radiation XRPD pattern of the nearly amorphous compound of formula (I) are shown in Table 2 below:
[0116] Table 2. XRPD pattern analysis data of the nearly amorphous compound of formula (I)
[0117] The present invention also provides the use of the compound of formula (I) and its crystal form in the preparation of a medicament for treating psoriasis and / or inflammatory bowel disease.
[0118] The present invention also provides the use of the Form 1 crystal form of the compound of formula (I) in the preparation of a medicament for treating psoriasis and / or inflammatory bowel disease.
[0119] The present invention also provides the use of the nearly amorphous form of the compound of formula (I) in the preparation of a medicament for treating psoriasis and / or inflammatory bowel disease.
[0120] Technical Effects
[0121] The present invention provides a process for synthesizing a compound of formula (I) and a method for preparing a crystal form thereof, providing a new method for synthesizing pyrazolopyrazine compounds. The beneficial effects include: avoiding the continuous use of precious metal catalysts and boric acid reagents in multiple steps, being environmentally friendly and cost-effective; performing selective alkylation of pyrazole compounds, and significantly improving reaction yields; using chiral reagents for chiral resolution, avoiding the use of expensive chiral SFC separations, and achieving a final product with extremely high chiral purity; and facilitating purification in each reaction step, eliminating column chromatography purification throughout the process, reducing reaction costs, and achieving a short cycle and high efficiency. The crystal form of the compound of formula (I) has good chemical stability.
[0122] The compound of formula (I) exhibited good selective inhibition of TYK2 and / or JAK1 and / or JAK2 in in vitro activity tests of the four subtypes of kinases, JAK1, JAK2, JAK3, and TYK2. It has good oral bioavailability in mice, and a high exposure dose is conducive to producing good in vivo efficacy. The compound of the present invention has no significant effect on the body weight of animals in the IL-23-induced C57BL / 6 mouse auricle epidermal dysplasia model, can inhibit the increase in the thickness of the modeled side ears of mice to varying degrees, and has a good dose-effect relationship in reducing the weight of the modeled side ears of animals. Oral administration of the compound of formula (I) can significantly improve the degree of swelling of the paws of mice, improve the scores and relative scores, and have no significant effect on the body weight of the animals.
[0123] Definition and Description
[0124] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be construed as ambiguous or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears herein, it is intended to refer to the corresponding commercial product or its active ingredient.
[0125] Unless otherwise specified, use a solid wedge key. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond and straight dashed key Indicate the relative configuration of stereocenters with a wavy line Indicates a wedge-shaped solid key or dotted wedge key Or use a wavy line Indicates a straight solid bond or straight dashed key
[0126] Unless otherwise indicated, the term "isomer excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value or ee%) is 80%.
[0127] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are resolved by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).
[0128] The intermediate compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples of the present invention. Those skilled in the art can refer to the contents of the present invention to appropriately change the raw materials, process conditions, and other aspects to achieve corresponding other purposes. Such related changes do not depart from the contents of the present invention. All similar substitutions and modifications are obvious to those skilled in the art and are considered to be included within the scope of the present invention.
[0129] The chemical reactions of the present invention are carried out in suitable solvents that are compatible with the chemical transformations of the present invention and the reagents and materials required. To obtain the compounds of the present invention, it may sometimes be necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.
[0130] An important consideration in planning any synthetic route in this field is the selection of an appropriate protecting group for a reactive functional group, such as the amino group in the present invention.
[0131] For any given crystalline form, the relative intensity of the diffraction peaks can vary due to factors such as the preferred orientation caused by factors such as the crystal morphology, which is well known in the art of crystallography. Where there is a preferred orientation effect, the peak intensity changes, but the position of the diffraction peaks of the crystal form cannot be changed. In addition, for any given crystal form, there may be slight errors in the positions of the peaks, which is also well known in the art of crystallography. For example, due to changes in temperature during sample analysis, movement of the sample, or calibration of the instrument, the position of the peaks can move, and the measurement error of the 2θ value is sometimes about ± 0.200 degrees. Therefore, it is well known to those skilled in the art that this error should be taken into account when determining each crystalline structure.
[0132] DSC measures the transition temperatures of crystals when they absorb or release heat due to changes in their crystalline structure or melting. For the same crystalline form of the same compound, the error in thermal transition temperatures and melting points in consecutive analyses is typically within about 5°C or 3°C. When we say that a compound has a given DSC peak or melting point, this refers to the DSC peak or melting point ±5°C or ±3°C. DSC provides an auxiliary method for distinguishing different crystalline forms. Different crystalline forms can be identified by their different transition temperature characteristics. It should be noted that for mixtures, their DSC peaks or melting points may vary over a wider range. In addition, since decomposition is associated with the melting process of a substance, the melting temperature is related to the heating rate.
[0133] For the same crystal form, the TGA weight loss temperature may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the weight loss temperature may have an error of about ±5°C, or about ±3°C.
[0134] It should be noted that during the preparation of drug crystal forms, during the contact between drug molecules and solvent molecules, external conditions and internal factors may cause the solvent molecules to form a co-crystal with the compound molecules and remain in the solid material, which is difficult to avoid, thereby forming solvates, specifically including stoichiometric solvates and non-stoichiometric solvates. All such solvates are included within the scope of the present invention.
[0135] The structures of the compounds of the present invention can be confirmed by conventional methods well known to those skilled in the art. If the present invention relates to the absolute configuration of a compound, the absolute configuration can be confirmed by conventional techniques in the art. For example, single crystal X-ray diffraction (SXRD) is performed by collecting diffraction intensity data from a cultured single crystal using a Bruker D8 venture diffractometer, using CuKα radiation and a φ / ω scanning mode. After collecting relevant data, the crystal structure can be further analyzed using a direct method (Shelxs97) to confirm the absolute configuration.
[0136] Unless otherwise specified, DSC spectra are exothermic upwards.
[0137] All solvents used in the present invention are commercially available, and commercially available compounds are designated by their supplier catalog names. When adding a mixed solvent to a reaction solution, the individual solvents may be mixed first and then added to the reaction solution; or the individual solvents may be added sequentially to the reaction solution and mixed in the reaction system. The present invention uses the following abbreviations: eq represents equivalent; Boc represents tert-butyloxycarbonyl; EtOAc represents ethyl acetate; HATU represents 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; DBU represents 1,8-diazabicyclo[5.4.0]undec-7-ene; ACN represents acetonitrile; DIEA represents N,N-diisopropylethylamine; Im represents imidazole; DCM represents dichloromethane; DMF represents N,N-dimethylformamide; PPh3 represents triphenylphosphine; M represents mol / L or moles / liter; SFC represents supercritical fluid chromatography.
[0138] The compounds were named using conventional naming methods in the art or ChemDraw software, and commercially available compounds were named according to the supplier's catalog name.
[0139] The present invention will be described in detail below through examples, which are not intended to limit the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS
[0140] Figure 1 is an XRPD spectrum of the Form 1 crystalline form of the compound of formula (I);
[0141] Figure 2 is a DSC spectrum of the Form 1 crystal form of the compound of formula (I);
[0142] Figure 3 is a TGA spectrum of the Form 1 crystal form of the compound of formula (I);
[0143] FIG4 is an XRPD spectrum of the amorphous form of the compound of formula (I);
[0144] FIG5 is a DSC spectrum of the amorphous form of the compound of formula (I);
[0145] FIG6 is a TGA spectrum of the amorphous form of the compound of formula (I).
[0146] Instruments and analytical methods
[0147] Table 3. Instrument information and detection method parameters DETAILED DESCRIPTION
[0148] The present invention is described in detail below by way of examples, but is not intended to limit the present invention in any way. While the present invention has been described in detail herein, and specific embodiments thereof have been disclosed, it will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0149] Example 1: Preparation of compound of formula (I)
[0150] Step 1:
[0151] Dissolve compound a (2.5 kg, 12.02 mol, 1 equivalent) in tetrahydrofuran (25 L) (clear). Slowly add isopropylmagnesium chloride tetrahydrofuran solution (2M, 6.31 L, 1.05 equivalent) dropwise at 5°C under a nitrogen stream. (During the addition of the Grignard reagent, the system will become turbid and the temperature will rise; control it not to exceed 10°C.) Add until complete, then maintain stirring at this temperature for 30 minutes. Dissolve compound b (1.24 kg, 12.02 mol, 1.28 L, 1 equivalent) in tetrahydrofuran (2.5 L) and add at 5°C. After addition, raise the internal temperature to 30°C. Stir for 4 hours until the reaction becomes clear. The reaction system was cooled to 5-10°C, concentrated hydrochloric acid (12M, 1.20L, 1.2 equivalents) was diluted with water (10L) and added to the reaction solution to quench the reaction. Industrial salt (2kg) was then added to saturate the aqueous phase. The mixture was allowed to stand for stratification, and the organic phase was separated. The aqueous phase was then extracted three times with a tetrahydrofuran / ethyl acetate mixed solvent (1:1, 6L). The organic phases were combined and concentrated. Four batches of the above parallel reactions yielded compound c (6kg, crude product) as a yellow oily liquid, which solidified after standing for a period of time. The crude product was used directly in the next step. Step 2:
[0152] Compound c (1500 g, 12.08 mol, 1 equivalent) was dissolved in dichloromethane (24 L) and ethanol (6 L). Pyridinium tribromide (3.67 kg, 11.48 mol, 0.95 equivalent) was added at 10-15°C and stirred for 2 hours, maintaining an internal temperature of 25°C. TLC (petroleum ether:ethyl acetate = 1:1) indicated the reaction was complete. Water (5 L) was added to the reaction mixture to quench the reaction. The layers were separated, and the aqueous phase was further extracted with dichloromethane (3 L x 3). The organic phases were combined and concentrated to yield the crude product. Ethanol / petroleum ether (1:3, 3 volumes) was added to the crude product, slurried, filtered, and the filter cake washed with ethanol / petroleum ether (1:3) and dried in a vacuum oven (50°C). Four parallel batches of the above reaction yielded compound d (7 kg, crude) as a light yellow solid. 1 H NMR (400MHz, CDCl3) δ7.99(s,1H),7.97(s,1H),4.19(s,2H),3.97(s,3H).
[0153] Step 3:
[0154] Compound e (1.09 kg, 8.62 mol, 1 equivalent) and compound d (1750 g, 8.62 mol, 1 equivalent) were dissolved in tetrahydrofuran (20 L). After the solution cleared, magnesium bromide (334.08 g, 1.72 mol, 95% purity, 0.20 equivalent) was added. N,N-diisopropylethylamine (1.34 kg, 10.34 mol, 1.80 L, 1.2 equivalent) was slowly added dropwise at 15-20°C over 3 hours. The reaction was maintained at this temperature and continued for 15 hours. Water (5 L) and ethyl acetate (10 L) were added to the reaction solution, and the layers were separated. The aqueous phase was extracted with dichloromethane (5 L x 2), and the organic phases were combined and concentrated. Four batches of the above reaction were repeated to obtain compound f (10 kg, crude) as a light yellow solid. LCMS (ESI): m / z: 249.1 [M+1] + .
[0155] Step 4:
[0156] Compound f (1.25 kg, 5.04 mol, 1 equivalent) and ammonium acetate (1500 g, 19.46 mol, 3.86 equivalents) were dissolved in ethanol (5 L). The reaction mixture was stirred in an autoclave at 120°C for 16 hours. The reaction mixture was removed from the autoclave, the solvent was concentrated under vacuum, and water (5 L) was added for slurrying. The mixture was filtered and the filter cake was washed with water. The filter cakes from eight parallel batches of the above reactions were combined and dried in a vacuum oven (80°C) to obtain compound g (3.9 kg, 44.98% yield) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ11.45(br s,1H),8.28(s,1H),8.10(s,1H),8.04(s,1H),7.88(s,1H),6.99(s,1H),3.87(s,3H).
[0157] Step 5:
[0158] Compound g (1300 g, 6.04 mol, 1 equivalent) was dissolved in acetonitrile (26 L), and phosphorus oxychloride (5.56 kg, 36.24 mol, 3.38 L, 6 equivalents) was added. The reaction mixture was stirred at 90°C for 12 hours. The reaction mixture was concentrated to obtain a crude product. Water (40 L) was added to the crude product and stirred for 30 minutes. The product was filtered and the filter cake was washed with water (5 L x 5) until the pH of the aqueous phase reached 6-7. The filter cake was then dried in a vacuum oven (80°C). Three batches of the above reaction were repeated to obtain compound h (3.7 kg, 87.38% yield) as an off-white solid. LCMS (ESI): m / z: 234.0 [M+1] + .
[0159] Step 6:
[0160] Compound h (1850 g, 7.92 mol, 1 equiv), compound i (2.31 kg, 8.31 mol, 1.05 equiv), [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (173.80 g, 237.53 mmol, 0.03 equiv), and sodium carbonate (2.10 kg, 19.79 mol, 2.5 equiv) were dissolved in dioxane (20 L) and water (4 L). The system was purged with nitrogen three times, and the reaction solution was stirred at 80°C under a nitrogen atmosphere for 12 hours. The reaction solution was cooled to 20°C, and water (15 L) and ethyl acetate (10 L) were added, stirred, and filtered. The mother liquor was allowed to stand and separate, and the aqueous phase was extracted once with ethyl acetate (5 L). The organic phases were combined, and mercaptosilica gel (1 kg) was added. The mixture was stirred at 50°C for 12 hours, filtered directly, and the filtrate was concentrated. Two batches of the above parallel reactions yielded compound j (5.53 kg, crude product) as a yellow solid. LCMS (ESI): m / z: 350.2 [M+1] + .
[0161] Step 7:
[0162] Compound j (3 kg, 8.59 mol, 1 equivalent) was dissolved in dichloromethane (30 L), and hydrochloric acid / ethyl acetate (4 M, 4.13 L, 2.10 equivalents) was added thereto. The reaction solution was stirred at 20 ° C for 12 hours. The reaction solution was directly filtered, the filtrate was discarded, and the filter cake was washed with dichloromethane (5 L) to obtain a light yellow solid. The solid was returned to the 50 L kettle, water (30 L) was added, and sodium carbonate aqueous solution (10 L, sodium carbonate (1.00 kg, 9.45 mol, 1.2 equivalents), pH 9-10) was added in several portions, and slurry was performed at 20 ° C for 12 hours. Filter, wash the filter cake with water, and dry in a vacuum drying oven (80 ° C). Two batches of the above parallel reactions gave compound k (3.9 kg, yield 93.39%) as a yellow solid. LCMS (ESI): m / z: 266.1 [M+1] + .
[0163] Step 8:
[0164] Compound 1 (3 kg, 19.46 mol, 1 equivalent) was dissolved in ethanol (18 L). Sulfuric acid (190.86 g, 1.95 mol, 103.73 mL, 0.1 equivalent) was added at 20°C. The reaction mixture was then stirred at 90°C for 2 hours. Water (15 L) and ethyl acetate (10 L) were added to the reaction mixture under ice-cooling, stirred, and extracted with ethyl acetate (10 L x 2). The organic phases were combined, washed with aqueous sodium chloride (10 L), dried over anhydrous sodium sulfate, and spin-dried to yield compound m (6.9 kg, 97.30% yield) as a brown liquid. 1H NMR (400MHz, CDCl3) δ4.07-4.00(m,2H),3.07-2.99(m,3H),2.98-2.95(m,2H),2.48-2.39(m,2H),2.38-2.29(m,2H),1.17-1.14(m,3H).
[0165] Step 9:
[0166] Compound n (4.52 kg, 20.17 mol, 4.00 L, 1.05 equivalents) was dissolved in tetrahydrofuran (30 L). Compound m (3.5 kg, 19.21 mol, 1 equivalent), lithium bromide (2.50 kg, 28.81 mol, 1.5 equivalents), and triethylamine (2.92 kg, 28.81 mol, 4.01 L, 1.5 equivalents) were added at 0°C. The reaction solution was then stirred at 25°C for 12 hours. Water (10 L) was added to the reaction solution, which was then extracted with ethyl acetate (10 L*3). The organic phases were combined, washed with aqueous sodium chloride (10 L), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was dissolved in petroleum ether / ethyl acetate (10:1, 12 L) and purified by column chromatography (petroleum ether / ethyl acetate = 10:1) to obtain compound o (9.3 kg, 92.50% yield) as a yellow liquid. LCMS (ESI): m / z: 253.0 [M+1] + .1H NMR (400MHz, CDCl3) δ5.50(br s,1H),4.13-3.92(m,4H),3.07(br s,1H),2.98(br s,1H),2.95-2.84(m,1H),2.77(br s,1H),2.70(br s,1H),2.32-2.12(m,4H),1.20-1.08(m,6H).
[0167] Step 10:
[0168] Acetonitrile (20 L), compound k (1.0 kg, 3.48 mol, 1 equivalent), 1,8-diazabicyclo[5.4.0]undec-7-ene (555 g, 3.66 mol, 1.05 equivalent), and compound o (945 g, 3.48 mol, 1 equivalent) were added sequentially to a 50-L reactor at 20-30°C. The temperature was raised to 85-95°C (internal temperature 82°C) and stirred for 14 hours to yield compound p. The reactor was cooled to 20-30°C, and aqueous sodium hydroxide solution (20 L; 417.6 g sodium hydroxide dissolved in 20 L of water) was added and stirred for 2 hours. Concentrated hydrochloric acid (1.25 L) was added to the reactor at 20-30°C to adjust the pH to 4-5, and the mixture was stirred at this temperature for 12 hours. The mixture was filtered, and the filter cake was washed with water (5 L). The filter cakes obtained from two batches of the above parallel reactions were dried under vacuum at 80°C for 72 hours to give compound q (2.7 kg, 74.94% yield) as a light yellow powder. LCMS (ESI): m / z: 462.2 [M+1] + .
[0169] Tetrahydrofuran (25 L), water (1.5 L), compound q (1.7 kg, 3.37 mol, 1 eq), and (R)-(+)-N-benzyl-1-phenylethylamine (1.5 kg, 7.08 mol, 2.1 eq) were added sequentially to a 50 L reactor at 20-30°C. The mixture was stirred at 20-30°C for 1 hour, then heated to 73°C and stirred for 2 hours. The mixture was then cooled to 20-30°C and stirred at this temperature for 12 hours. The reaction mixture was filtered, and the filter cake was washed three times with tetrahydrofuran / water (16.5:1; 10 L). The filtrate was concentrated under reduced pressure and slurried with aqueous sodium carbonate solution (15 L; 855 g sodium carbonate dissolved in 15 L of water) for 1 hour. Ethyl acetate (10 L) was added, and stirring continued for 1 hour. The mixture was allowed to stand for separation, and the aqueous phase was washed again with ethyl acetate (10 L). The organic phase was discarded. The aqueous phase was pumped into the reactor, acetonitrile (1.5 L, water in the reactor: acetonitrile = 10:1) was added, and the pH was adjusted to 4-5 with concentrated hydrochloric acid (1.3 L). The mixture was stirred at 20-30 ° C for 12 hours. A white solid was generated. The reaction solution was filtered. The filter cakes obtained from two batches of the above parallel reactions were vacuum dried at 70 ° C for 12 hours to obtain compound r (1.4 kg) as an off-white powder. At 20-30°C, tetrahydrofuran (33 L), water (2 L), the above-mentioned compound r (1.4 kg, 3.03 mol, 1 equivalent) and (S)-(-)-N-benzyl-1-phenylethylamine (1.35 kg, 6.37 mol, 2.1 equivalents) were added sequentially into a 50 L reactor, stirred at 20-30°C for 1 hour, heated to 73°C and stirred for 2 hours, cooled naturally to 20-30°C and stirred at this temperature for 12 hours. The reaction solution was filtered and the filter cake was washed three times with tetrahydrofuran / water (16.5:1; 10 L). Tetrahydrofuran (33 L), water (2 L), and the filter cake were added sequentially to a 50 L reactor at 20-30°C. The mixture was stirred at 20-30°C for 1 hour, heated to 73°C, stirred for 2 hours, cooled naturally to 20-30°C, and stirred at this temperature for 12 hours. The reaction mixture was filtered, and the filter cake was washed three times with tetrahydrofuran / water (16.5:1; 20 L). The filter cake was slurried with aqueous sodium carbonate solution (20 L; 771.68 g of sodium carbonate dissolved in 20 L of water) for 1 hour, and ethyl acetate (10 L) was added. Stirring was continued for 1 hour. The mixture was allowed to stand for separation, and the aqueous phase was washed again with ethyl acetate (20 L). The two organic phases were discarded. The aqueous phase was pumped into the reactor, acetonitrile (2 L; water in the reactor: acetonitrile = 10:1) was added, and the pH was adjusted to 4-5 with concentrated hydrochloric acid (1.18 L). The mixture was stirred at 20-30 ° C for 12 hours to produce a white solid. The reaction solution was filtered and the filter cake was dried in vacuo at 70 ° C for 12 hours to obtain compound r (1.08 kg, yield 31.75%) as an off-white powder.SFC analysis method (column type: Chiralcel OJ-3 100*4.6mm ID, 3μm; mobile phase: A: CO2; B: methanol (0.05% diethylamine); B phase gradient: 5%-40% for 4 min, hold at 40% for 2.5 min, then 5% for 1.5 min; flow rate: 2.8 mL / min); retention time: 3.285 min; ee% = 99.02%.
[0170] Step 11:
[0171] At 15-25°C, N,N-dimethylformamide (3 L), compound r (1.08 kg, 2.32 mol, 1 eq), N,N-diisopropylethylamine (1.62 L, 9.29 mol, 4 eq), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.86 kg, 4.88 mol, 2.1 eq), and ammonium chloride (261.01 g, 4.88 mol, 2.1 eq) were added sequentially to a 10-L three-necked flask. The reaction solution was stirred at 15-25°C for 1 hour. The temperature in the 50-L reactor was controlled at 20°C. Dichloromethane (20 L) was first pumped into the reactor under reduced pressure, then the reaction solution in the 10-L three-necked flask was pumped into the reactor, and finally, additional dichloromethane (10 L) was pumped into the reactor. The temperature was maintained for 16 hours. The mixture was filtered and the filter cake was washed with dichloromethane (5 L). The filter cake was dried under vacuum at 50°C for 16 hours to give compound s (1.055 kg, yield 82.77%) as an off-white powder. LCMS (ESI): m / z: 460.2 [M+1] + .
[0172] Step 12:
[0173] To a 50-L reactor, add dichloromethane (20 L) at 20-30°C, then cool to 0°C with stirring. Compound s (1.055 kg, 1.94 mol, 1 equivalent) and triethylamine (1.08 L, 7.75 mol, 4 equivalents) were then added sequentially at 0°C. Trifluoroacetic anhydride (1.08 L, 7.75 mol, 4 equivalents) was then slowly added dropwise to the reactor at 0°C. The reactor was heated to 15-25°C and stirred at this temperature for 1 hour. The reaction was quenched with saturated aqueous sodium carbonate (10 L) and extracted with dichloromethane (5 L). The organic phase was concentrated and slurried with methanol / methyl tert-butyl ether (12 L, 5:1) for 12 hours, yielding a white solid. The filter cake was filtered and dried under vacuum at 50°C for 12 hours to yield compound (I)-crude (670 g, 82.77% yield) as an off-white powder. LCMS (ESI): m / z: 424.1 [M+1] +.1H NMR (400MHz, DMSO-d6) δ9.02(s,1H),8.79(s,1H),8.46(s,1H),8.36(s,1H),8.19(d,J=2.5Hz,1H),8.15(s,1H),7.43(dd,J= 0.8,2.5Hz,1H),3.91(s,3H),3.36-3.34(m,2H),3.33-3.24(m,2H),3.03-2.93(m,2H),2.68-2.58(m,3H),2.41-2.30(m,2H).
[0174] Step 13:
[0175] To a 10-L three-necked flask, methanol (6.7 L) and compound (I)-crude (335 g, 0.79 mol, 1 equivalent) were added sequentially at 20-30°C. The reaction flask was stirred at 90°C for 1 hour until the reaction solution became clear. The reaction solution was filtered while hot, and the resulting filtrate was stirred at 20-30°C for 12 hours, resulting in the precipitation of a white solid. The reaction solutions from two parallel reactions were combined and filtered, and the filter cake was vacuum-dried at 50°C for 12 hours to obtain filter cake 1 (576 g).
[0176] To a 10-L three-necked flask, add methanol (5.76 L) and filter cake 1 (288 g, 0.68 mol, 1 equivalent) sequentially at 20-30°C. Stir the reaction flask at 90°C for 1 hour until the reaction solution becomes clear. Remove heating, slowly cool to 20-30°C, and stir at this temperature for 12 hours, until a white solid precipitates. Combine the reaction solutions from two parallel reactions, filter them, and vacuum dry the filter cake at 50°C for 12 hours to obtain filter cake 2 (439 g).
[0177] At 20-30°C, methanol (8.78 L), filter cake 2 (439 g, 1.04 mol, 1 equivalent), and triethylamine (72.25 mL, 0.52 mol, 0.5 equivalent) were added sequentially to a 10-L three-necked flask. The reaction flask was stirred at 90°C for 1 hour until the reaction solution became clear. Heating was stopped, the temperature was slowly lowered to 20-30°C, and stirred at this temperature for 12 hours, resulting in the precipitation of a white solid. The reaction solution was filtered, and the filter cake was vacuum-dried at 50°C for 12 hours to yield compound (I) (370 g, 55.23% yield) as an off-white powder. LCMS (ESI): m / z: 424.2 [M+1] + SFC analysis method (column: Cellulose 2 100 x 4.6 mm ID, 3 μm; mobile phase: A: CO2; B: methanol (0.05% diethylamine); phase B gradient: 40%; flow rate: 2.8 mL / min); retention time: 5.586 min; ee% = 100%.
[0178] Example 2: Preparation of a nearly amorphous form of the compound of formula (I)
[0179] The compound of formula (I) (2 g, 4.72 mmol) was purified by preparative HPLC (column: Phenomenex C18 80*40 mm*3 μm; mobile phase: [water (NH3H2O+NH4HCO3)-acetonitrile]; acetonitrile%: 36%-66%; 8 min) and then lyophilized to obtain a nearly amorphous compound of formula (I) (1.7 g, yield: 83.73%) as a white solid.
[0180] About 50 mg of a nearly amorphous sample of the compound of formula (I) was taken, 1 mL of water was added, and the slurry was allowed to crystallize at room temperature for 30 minutes, centrifuged, and dried under vacuum at 40°C overnight. The solid was then subjected to XRPD characterization. The results showed that it was nearly amorphous.
[0181] About 50 mg of a nearly amorphous sample of the compound of formula (I) was taken and placed in a centrifuge tube. The sample was placed in a bottle filled with water at room temperature for 3 days. The solid was then subjected to XRPD characterization. The results showed that the sample was nearly amorphous.
[0182] Example 3: Preparation of Form 1 of the compound of formula (I)
[0183] The compound of formula (I) obtained in Example 1 is a Form 1 crystal form. Other preparation methods of the Form 1 crystal form are shown in Table 4 below:
[0184] Table 4. Crystal preparation method
[0185] 1. Volatile crystallization method
[0186] Approximately 50 mg of a nearly amorphous sample of the compound of formula (I) was taken and added to the corresponding solvent (Table 5). The sample was dissolved and filtered, and the filtrate was evaporated to dryness by small aperture at the corresponding temperature (Table 5). The solid was then characterized by XRPD. The results are shown in Table 5.
[0187] Table 5. Results of Form 1 prepared by volatile crystallization method
[0188] 2. Slurry crystallization method
[0189] ① Approximately 50 mg of Form 1 crystalline form of the compound of Formula (I) was separately added to the corresponding solvent (Table 6). The slurry was then placed at the corresponding temperature (Table 6) for 3 days, centrifuged, and dried under vacuum at 40°C overnight. The solid was then characterized by XRPD. The results are shown in Table 6.
[0190] Table 6. Results of Form 1 crystal prepared by slurry crystallization method
[0191] ② Approximately 50 mg of a nearly amorphous sample of the compound of formula (I) was taken and the corresponding solvent (see Table 7) was added. The slurry was then placed at the corresponding temperature (see Table 7) for 30 minutes, centrifuged, and dried under vacuum at 40°C overnight. The solid was then characterized by XRPD. The results are shown in Table 7.
[0192] Table 7. Results of Form 1 crystal prepared by slurry crystallization method
[0193] 3. Cooling crystallization method
[0194] ① Approximately 50 mg of Form 1 crystalline form of the compound of formula (I) was taken, 5 mL of ethanol was added, and the solution was dissolved in a 60°C water bath. The solution was then transferred to an ice-salt bath and stirred for 0.5 hours to precipitate a solid. The solution was centrifuged and dried in a vacuum oven at 40°C overnight. The solid was characterized by XRPD, which showed Form 1 crystalline form.
[0195] ② Approximately 50 mg of a nearly amorphous sample of the compound of formula (I) was taken and added to the corresponding solvent (see Table 8). The sample was dissolved in a 60°C water bath with stirring for 5 minutes to precipitate. Stirring was continued for 0.5 hours, and the sample was centrifuged. The solid was collected and characterized by XRPD. The results are shown in Table 8.
[0196] Table 8. Results of Form 1 prepared by cooling crystallization
[0197] 4. Antisolvent Crystallization
[0198] Approximately 50 mg of Form 1 of the compound of Formula (I) was added to Solvent 1 (see Table 9) and dissolved. The sample solution was then added dropwise to the stirring Solvent 2 at room temperature. Stirring was continued for 2 hours, followed by centrifugation and drying under vacuum at 40°C overnight. The solid was then characterized by XRPD. The results are shown in Table 9.
[0199] Table 9. Results of Form 1 crystal prepared by antisolvent crystallization
[0200] 5. Gas-solid diffusion crystallization method
[0201] About 50 mg of a nearly amorphous sample of the compound of formula (I) was placed in a centrifuge tube and allowed to stand in a bottle containing acetone at room temperature for 3 days. The solid was taken for XRPD characterization, and the results showed Form 1 crystal form.
[0202] Example 4: Stability test of Form 1 crystal of the compound of formula (I)
[0203] In accordance with the "Guiding Principles for Stability Testing of APIs and Pharmaceutical Products" (Chinese Pharmacopoeia 2020 Edition, Part IV, General Rules 9001), to evaluate the solid-state stability of Form 1 of the compound of Formula (I), stability studies were conducted under influencing factors (high temperature, high humidity, and light) and accelerated conditions (40°C / 75% RH and 60°C / 75% RH). The test results are shown in Tables 10 and 11 below.
[0204] Table 10. Crystal stability results: influencing factors test
[0205] Table 11. Crystal stability results: accelerated test
[0206] Conclusion: The Form 1 crystalline form of the compound of formula (I) did not undergo significant changes in crystalline form under all stability conditions and had good chemical stability.
[0207] Biological activity test
[0208] Experimental Example 1: In vitro activity test of Jak1, Jak2, Jak3, and Tyk2 kinases
[0209] Experimental Materials
[0210] Recombinant human JAK1, JAK2, JAK3, Tyk2 proteases, major instruments and reagents were provided by Eurofins in the UK.
[0211] Experimental methods
[0212] JAK2, JAK3, and TYK2 dilutions: 20 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 1 mM EDTA, 0.01% Brij-3 5.5% glycerol, 0.1% β-mercaptoethanol, 1 mg / mL BSA; JAK1 dilutions: 20 mM TRIS, 0.2 mM EDTA, 0.1% β-mercaptoethanol, 0.01% Brij-3 5.5% glycerol. Compounds of Formula (I) were prepared as 100% DMSO solutions to a final assay concentration of 50-fold. Test compounds were serially diluted 3-fold to a final concentration of 9 concentrations ranging from 10 μM to 0.001 μM. DMSO was used in the assay reaction at 2%. The working stock of the compound was added to the assay wells as the first component of the reaction, followed by the addition of the remaining components according to the assay protocol detailed below.
[0213] JAK1(h) enzyme reaction
[0214] JAK1(h) was incubated with 20 mM Tris / HCl pH 7.5, 0.2 mM EDTA, 500 μM MGEEPLYWSFPAKKK, 10 mM magnesium acetate and [γ- 33 The cells were incubated with [P]-ATP (activity and concentration determined as needed). The reaction was initiated by adding the Mg / ATP mixture and incubated at room temperature for 40 minutes before being terminated by the addition of 0.5% phosphoric acid. 10 μL of the reaction mixture was then spotted onto a P30 filter pad and washed three times with 0.425% phosphoric acid and once with methanol over a 4-minute period, dried, and scintillation counted.
[0215] JAK2(h) enzyme reaction
[0216] JAK2(h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 100 μM KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC, 10 mM magnesium acetate, and [γ-33P]-ATP (activity and concentration determined as needed). The reaction was initiated by the addition of the Mg / ATP mixture and incubated at room temperature for 40 minutes before being terminated by the addition of 0.5% phosphoric acid. 10 μL of the reaction was then spotted onto a P30 filter pad and washed three times with 0.425% phosphoric acid and once with methanol over a 4-minute period, dried, and scintillation counted.
[0217] JAK3(h) enzyme reaction
[0218] JAK3(h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 500 μM GGEEEEYFELVKKKK, 10 mM magnesium acetate and [γ- 33 The cells were incubated with [P]-ATP (activity and concentration determined as needed). The reaction was initiated by adding the Mg / ATP mixture and incubated at room temperature for 40 minutes before being terminated by the addition of 0.5% phosphoric acid. 10 μL of the reaction mixture was then spotted onto a P30 filter pad and washed three times with 0.425% phosphoric acid and once with methanol over a 4-minute period, dried, and scintillation counted.
[0219] TYK2(h) enzyme reaction
[0220] TYK2(h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 250 μM GGMEDIYFEFMGGKKK, 10 mM magnesium acetate and [γ- 33The cells were incubated with [P]-ATP (activity and concentration determined as needed). The reaction was initiated by adding the Mg / ATP mixture and incubated at room temperature for 40 minutes before being terminated by the addition of 0.5% phosphoric acid. 10 μL of the reaction mixture was then spotted onto a P30 filter pad and washed three times with 0.425% phosphoric acid and once with methanol over a 4-minute period, dried, and scintillation counted.
[0221] Data Analysis
[0222] IC 50 The results were obtained by analysis using XLFIT5 (205 formula) from IDBS, as shown in Table 12.
[0223] Table 12. Results of in vitro screening tests of the compounds of the present invention
[0224] Conclusion: The compound of formula (I) exhibited good selective inhibition of TYK2 and / or JAK1 and / or JAK2 in the in vitro activity test of the four kinase subtypes JAK1, JAK2, JAK3 and TYK2.
[0225] Experimental Example 2: Pharmacokinetic (PK) test
[0226] The clear solution obtained after dissolving the test compound was administered to male mice (balb / c) via tail vein injection and oral gavage, respectively. After administration of the test compound, blood was collected from the mandibular vein at 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours for the intravenous injection group (1 mg / kg) and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours for the oral gavage group (3 mg / kg), and plasma was obtained after centrifugation. The plasma concentration was determined by LC-MS / MS, and the relevant pharmacokinetic parameters were calculated using WinNonlinTM Version 6.3 pharmacokinetic software using the non-compartmental model linear logarithmic trapezoidal method. The test results are shown in Table 13:
[0227] Table 13. PK test results of the compound of formula (I) in mice Note: T 1 / 2 : half-life; C max : peak concentration; Cl: clearance; Vd: volume of distribution; AUC: 0-inf : The area under the plasma concentration-time curve from time 0 to infinity; Bioavailability: bioavailability.
[0228] Conclusion: The compound of formula (I) has good oral bioavailability in mice, and a higher exposure is conducive to producing good in vivo efficacy.
[0229] Experimental Example 3: Efficacy test in a mouse psoriasis model
[0230] Objective: The purpose of this experiment was to induce a psoriasis-like skin lesion model in mice by intradermal injection of IL-23 into the auricle, and to evaluate the preventive and therapeutic effects of the test substance on IL-23-induced psoriasis-like skin lesions in mice.
[0231] Methods: After the acclimation period, 50 mice were randomly assigned to five groups (10 mice each) using the Excel complete randomization method: a vehicle (0.5% MC & 0.5% Tween 80) control group, a modeling group, and a compound of formula (I) (10, 20, and 50 mg / kg) group. Except for the vehicle control group, all other groups received intradermal injections of IL-23 (3 μg / 10 μL / mouse / day, QD) into the right ear for 8 consecutive days (D1-D8). The control group received intradermal injections of an equal volume of saline solution (10 μL / mouse / day, QD) into the right ear for 8 consecutive days (D1-D8). Simultaneously with modeling, the vehicle and test drug were orally administered twice daily (Bid) at 6-hour intervals for 8 consecutive days (D1-D8). Animal body weights were monitored every two days during the dosing period. The thickness of the right ear of the mice was measured and the appearance of the auricle was observed and scored on Days 1, 3, 5, 7 (all before IL-23 injection), and 9. At the end of the experiment (Day 10), the ear on the modeling side was removed, and an ear piece was punched along the edge of the auricle with an 8mm punch and weighed. The punched right ear piece was fixed in formalin and stained for histopathology (H&E).
[0232] The experimental results are shown in Tables 14-17.
[0233] Table 14. Effects of oral administration of the test substances twice a day for 8 consecutive days on the body weight of mice in the IL-23-induced mouse ear epidermal hyperplasia model
[0234] Table 15. Effects of oral administration of the test substances twice daily for 8 consecutive days on ear thickness in mice with IL-23-induced auricular epidermal hyperplasia model ## P<0.01vs.Control *P<0.05,**P<0.01vs.Model
[0235] Table 16. Effects of the test substances on the ear weight of mice in the IL-23-induced mouse auricle epidermal hyperplasia model ## P<0.01vs.Control **P<0.01vs.Model
[0236] Table 17. Effects of oral administration of the test substances twice a day for 8 consecutive days on the total score of IL-23-induced auricular epidermal hyperplasia in mice ##P<0.01 vs. Control **P<0.01 vs. Model Note: IL-23: interleukin-23.
[0237] in conclusion:
[0238] ①. In the IL-23-induced C57BL / 6 mouse auricle epidermal dysplasia model, oral administration of the compound of formula (I) (10, 20, 50 mg / kg) twice a day for 8 consecutive days had no significant effect on the body weight of the animals in the IL-23-induced C57BL / 6 mouse auricle epidermal dysplasia model.
[0239] ②. Effect on Pleurotus Thickness in Animal Models: Compound 1 at 10 and 20 mg / kg significantly reduced Pleurotus thickness in the model mice starting from day 5. Compound (I) at a dose of 50 mg / kg significantly reduced Pleurotus thickness in the model mice starting from day 3. A good dose-effect relationship was observed across the three dose groups. This indicates that Compound (I) (10, 20, and 50 mg / kg) inhibited the increase in Pleurotus thickness in the model mice to varying degrees.
[0240] ③. Effect on the weight of the ear on the modeled side of the animal: Oral administration of the compound of formula (I) (10, 20, 50 mg / kg) twice a day for 8 consecutive days by gavage can significantly reduce the weight of the ear on the modeled side of the animal, and the three dosage groups showed a good dose-effect relationship in reducing the weight of the ear on the modeled side of the animal.
[0241] ④. Effect on the total score of the ear on the modeling side of the animal: Oral administration of the compound of formula (I) (10, 20, 50 mg / kg) twice a day for 8 consecutive days can significantly reduce the total score of the affected ear of the mice from D5 to D9, showing good efficacy and a good dose-effect relationship.
Claims
1. A method for preparing a compound of formula (I), It is characterized in that It includes a chiral resolution method for compound q, in, The chiral reagent is selected from chiral reagent 1 or chiral reagent 2; The chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, and the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine; The mixed solvent is selected from solvent 2 and solvent 3; The solvent 2 is tetrahydrofuran, and the solvent 3 is water.
2. The method for preparing the compound of formula (I) according to claim 1, wherein: The molar ratio of compound q to the chiral reagent is 1:2 to 1:2.5, preferably 1:2.
1.
3. The method for preparing the compound of formula (I) according to claim 1, wherein: The volume ratio of the mixed solvent is tetrahydrofuran: water = 15:1 to 20:1; preferably 16.5:
1.
4. The method for preparing the compound of formula (I) according to claim 1, wherein: The chiral resolution method of compound q also includes a further purification step.
5. The method for preparing the compound of formula (I) according to claim 1, comprising selectively alkylating compound d and compound e. in, Reagent 1 is magnesium bromide; Base 2 is DIEA; Solvent 4 is tetrahydrofuran.
6. The method for preparing the compound of formula (I) according to claim 5, wherein: The molar ratio of compound e, compound d and reagent 1 is 1:0.8:0.1 to 1:1.2:0.3, preferably 1:1:0.
2.
7. A method for preparing a compound of formula (I) according to claim 1, comprising the synthesis of intermediate k, The reagent 1 is selected from magnesium bromide; The base 2 is selected from DIEA; The solvent 4 is selected from tetrahydrofuran; The reagent 2 is selected from ammonium acetate; The solvent 5 is selected from ethanol; The halogenating agent is selected from phosphorus oxychloride; The solvent 6 is selected from acetonitrile; The catalyst is selected from [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride; The base 3 is selected from sodium carbonate; The solvent 7 is selected from dioxane; The solvent 8 is selected from water; The acidic system 2 is selected from hydrochloric acid / ethyl acetate solution; The solvent 9 is selected from dichloromethane.
8. The method for preparing the compound of formula (I) according to claim 1, further comprising synthesizing the compound of formula (I) from compound 1, The acidic system 3 is selected from sulfuric acid; The solvent 10 is selected from ethanol; The base 4 is selected from triethylamine; The solvent 11 is selected from tetrahydrofuran; The reagent 3 is selected from lithium bromide; The solvent 1 is selected from acetonitrile; The alkaline system 1 is selected from an aqueous sodium hydroxide solution; The acidic system 1 is selected from concentrated hydrochloric acid; The chiral reagent is selected from chiral reagent 1 or chiral reagent 2; The chiral reagent 1 is (R)-(+)-N-benzyl-1-phenylethylamine, and the chiral reagent 2 is (S)-(-)-N-benzyl-1-phenylethylamine; The mixed solvent is selected from solvent 2 and solvent 3; The solvent 2 is tetrahydrofuran, and the solvent 3 is water; The reagent 4 is selected from ammonium chloride; The base 5 is selected from DIEA; The condensing agent is selected from HATU; The solvent 12 is selected from DMF; The reagent 4 is selected from trifluoroacetic anhydride; The base 6 is selected from triethylamine; The solvent 13 is selected from dichloromethane; The solvent 14 is selected from methanol.
9. The Form 1 crystalline form of the compound of formula (I) shown below, It is characterized in that The Cu Kα radiation X-ray powder diffraction spectrum thereof has characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200° and 12.852±0.200°.
10. The Form 1 crystal form of the compound of formula (I) according to claim 9, wherein its X-ray powder diffraction spectrum, expressed by 2θ angle, comprises at least 6, 7, 8 or 9 diffraction peaks selected from the following: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°.
11. The Form 1 crystalline form of the compound of formula (I) according to claim 10, having an X-ray powder diffraction spectrum with characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200° and 19.105±0.200°.
12. The Form 1 crystalline form of the compound of formula (I) according to claim 11, whose X-ray powder diffraction spectrum has characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°, 20.875±0.200° and 21.210±0.200°.
13. The Form 1 crystal form of the compound of formula (I) according to claim 12, wherein the X-ray powder diffraction spectrum has characteristic diffraction peaks at the following 2θ angles: 8.087±0.200°, 9.379±0.200°, 11.188±0.200°, 12.852±0.200°, 16.163±0.200°, 18.306±0.200°, 18.626±0.200°, 19.105±0.200°, 19.447±0.200°, 20.666±0.200°, 20.875±0.200°, 21.210±0.200°, 22.417±0.200°, 23.446±0.200°, 24.043±0.200° and 24.402±0.200°.
14. The Form 1 crystal form of the compound of formula (I) according to claim 13, wherein the X-ray powder diffraction spectrum has characteristic diffraction peaks at the following 2θ angles: 6.516°, 8.087°, 9.378°, 11.188°, 11.881°, 12.852°, 13.880°, 14.564°, 15.615°, 16.163°, 18.306°, 18.626°, 19.105°, 19.477°, 20.666°, 20.875°, 21.210°, 22.417°, 23.446° , 23.715°, 24.043°, 24.402°, 25.159°, 25.663°, 26.227°, 26.742°, 26.897°, 27.127°, 27.752°, 28.341°, 29.332°, 30.727°, 30.956°, 31.678°, 32.197°, 32.574°, 34.479°, 35.051°, 35.341°, 35.873°, 36.960°.
15. The Form 1 crystal form of the compound of formula (I) according to claim 9, whose XRPD pattern is shown in Figure 1.
16. The Form 1 crystal form of the compound of formula (I) according to claim 9, wherein the differential scanning calorimetry (DSC) curve thereof shows an endothermic peak starting point at 161.77°C ± 3.00°C.
17. The Form 1 crystal form of the compound of formula (I) according to claim 9, wherein the thermogravimetric analysis (TGA) curve thereof shows a weight loss of 0.3182% at 150.00°C±3.00°C.
18. Use of the Form 1 crystal form of the compound of formula (I) according to any one of claims 9 to 17 in the preparation of a medicament for treating psoriasis and / or inflammatory bowel disease.
Citation Information
Patent Citations
4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
CN107278203A
Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CN109071546A
Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
WO2020207476A1
Pyrazolo fused ring compound and use thereof
WO2023083200A1
CN202310544690A
